Business Context and Reporting Period
Company: 4D Molecular Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 24, 2026
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Hercules Capital, Inc.
Key Financial Metrics and Debt Structure
This filing details a new senior secured term loan facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
| Metric | Value/Detail |
|---|---|
| Total Facility Size | Up to $200.0 million |
| Initial Draw (Tranche 1A) | $20.0 million (drawn on Closing Date) |
| Tranche 1B Availability | $30.0 million (available until June 15, 2027) |
| Milestone Tranches (2A-4) | $100.0 million total (subject to milestones) |
| Discretionary Tranche (5) | $50.0 million (sole discretion of Hercules) |
| Maturity Date | June 1, 2031 |
| Interest Rate (Tranche 1A) | Greater of (Prime + 2.00%) or 8.75% |
| Interest Rate (Other Tranches) | Greater of (Prime + 2.50%) or 9.25% |
| Initial Facility Charge | $500,000 |
| Tranche Facility Charge | 1.00% of advances for Tranches 2-5 |
Material Changes and Covenants
The primary material change is the incurrence of new debt obligations secured by substantially all company assets, including intellectual property. The agreement imposes specific financial and performance covenants:
- Minimum Cash Covenant: Tested beginning Jan 1, 2028 (or earlier if borrowings exceed $25M/$50M thresholds). Requires maintaining cash equal to a specified percentage of outstanding obligations. Waived if market cap exceeds 7x outstanding obligations.
- Convertible Debt Redemption: If cash redemption occurs, cash must equal at least 125% of outstanding obligations.
- Performance Covenant: Tested 9 months after FDA approval of the lead product AND aggregate borrowings reach $75M. Requires meeting one of three conditions:
- Market cap > $750M AND cash > 50% of obligations; OR
- Cash > 125% of obligations; OR
- Trailing 6-month net product revenue > 70% of forecasted revenue.
Outlook, Risks, and Contingencies
Management Commentary: The filing does not contain explicit management commentary on future operational outlook beyond the terms of the loan agreement.
Risks and Contingencies:
- Default Acceleration: Upon an event of default, lenders may accelerate all obligations. Insolvency or bankruptcy events trigger automatic acceleration.
- Collateral Risk: Obligations are secured by substantially all assets, including intellectual property. Future subsidiaries may be required to guarantee obligations and pledge assets.
- Prepayment Penalties: Prepayments are subject to certain prepayment and exit fees.
Key Facts for Investor Verification
- Verify the exact amount of the initial $20.0 million draw and its impact on current liquidity.
- Monitor the company's progress toward the milestones required to access the $100.0 million in Tranches 2A through 4.
- Track the company's market capitalization relative to the 7x debt threshold to assess the applicability of the minimum cash covenant waiver.
- Confirm the status of the lead product candidate's FDA approval timeline, as this triggers the performance covenant testing period.
- Review the full text of the Loan and Security Agreement (to be filed as an exhibit to the Q2 2026 10-Q) for detailed definitions of "milestones" and "forecasted revenue."